Characterization of response to everolimus (EVE) in BOLERO-2: A phase 3 trial of EVE plus exemestane (EXE) in postmenopausal women with HR+, HER2-advanced breast cancer

被引：1
|
作者：
Burris, H.
Gnant, M.
Hortobagyi, G.
Hart, L.
Yardley, D. A.
Eakle, J.
Provencher, L.
Brechenmacher, T.
Saletan, S.
Taran, T.
Rugo, H.
机构：
[1] Sarah Cannon Res Inst, Nashville, TN USA
[2] Med Univ Vienna, Ctr Comprehens Canc, Vienna, Austria
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[4] Florida Canc Specialists, Sun City Ctr, FL USA
[5] Ctr Malad Sein Deschenes Fabia, Ste Foy, PQ, Canada
[6] Novartis Pharmaceut Corp SAS, New York, NY USA
[7] Novartis Pharmaceut, New York, NY USA
[8] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
来源：
CANCER RESEARCH | 2013年 / 73卷
关键词：
D O I：
10.1158/0008-5472.SABCS13-P2-16-17
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-16-17
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2
    J. Thaddeus Beck
    Gabriel N. Hortobagyi
    Mario Campone
    Fabienne Lebrun
    Ines Deleu
    Hope S. Rugo
    Barbara Pistilli
    Norikazu Masuda
    Lowell Hart
    Bohuslav Melichar
    Shaker Dakhil
    Matthias Geberth
    Martina Nunzi
    Daniel Y. C. Heng
    Thomas Brechenmacher
    Mona El-Hashimy
    Shyanne Douma
    Francois Ringeisen
    Martine Piccart
    [J]. Breast Cancer Research and Treatment, 2014, 143 : 459 - 467
  • [2] Everolimus plus exemestane as first-line therapy in HR+, HER2- advanced breast cancer in BOLERO-2
    Beck, J. Thaddeus
    Hortobagyi, Gabriel N.
    Campone, Mario
    Lebrun, Fabienne
    Deleu, Ines
    Rugo, Hope S.
    Pistilli, Barbara
    Masuda, Norikazu
    Hart, Lowell
    Melichar, Bohuslav
    Dakhil, Shaker
    Geberth, Matthias
    Nunzi, Martina
    Heng, Daniel Y. C.
    Brechenmacher, Thomas
    El-Hashimy, Mona
    Douma, Shyanne
    Ringeisen, Francois
    Piccart, Martine
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2014, 143 (03) : 459 - 467
  • [3] UPDATED RESULTS OF THE BOLERO-2 PHASE III TRIAL EVALUATING EVEROLIMUS (EVE) FOR POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER (ABC)
    Rugo, H.
    Piccart, M.
    Hortobagyi, G.
    Noguchi, S.
    Gnant, M.
    Campone, M.
    Bauly, H.
    Mukhopadhyay, P.
    Sahmoud, T.
    Baselga, J.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 46 - 46
  • [4] Triplet therapy with ribociclib, everolimus, and exemestane in women with HR+/HER2-advanced breast cancer
    Bardia, A.
    Modi, S.
    Oliveira, M.
    Campone, M.
    Ma, B.
    Dirix, L.
    Weise, A.
    Nardi, L.
    Zhang, V.
    Bhansali, S. G.
    Hewes, B.
    Chavez-MacGregor, M.
    [J]. CANCER RESEARCH, 2016, 76
  • [5] Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
    Denise A. Yardley
    Shinzaburo Noguchi
    Kathleen I. Pritchard
    Howard A. Burris
    José Baselga
    Michael Gnant
    Gabriel N. Hortobagyi
    Mario Campone
    Barbara Pistilli
    Martine Piccart
    Bohuslav Melichar
    Katarina Petrakova
    Francis P. Arena
    Frans Erdkamp
    Wael A. Harb
    Wentao Feng
    Ayelet Cahana
    Tetiana Taran
    David Lebwohl
    Hope S. Rugo
    [J]. Advances in Therapy, 2013, 30 : 870 - 884
  • [6] Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
    Yardley, Denise A.
    Noguchi, Shinzaburo
    Pritchard, Kathleen I.
    Burris, Howard A., III
    Baselga, Jose
    Gnant, Michael
    Hortobagyi, Gabriel N.
    Campone, Mario
    Pistilli, Barbara
    Piccart, Martine
    Melichar, Bohuslav
    Petrakova, Katarina
    Arena, Francis P.
    Erdkamp, Frans
    Harb, Wael A.
    Feng, Wentao
    Cahana, Ayelet
    Taran, Tetiana
    Lebwohl, David
    Rugo, Hope S.
    [J]. ADVANCES IN THERAPY, 2013, 30 (10) : 870 - 884
  • [7] AN OUTCOMES MODEL ASSESSING THE IMPACT OF EARLY DISCONTINUATION OF EVEROLIMUS (EVE) DUE TO STOMATITIS ON HEALTH AND PATIENT-REPORTED OUTCOMES IN POSTMENOPAUSAL WOMEN WITH HR+/HER2-ADVANCED BREAST CANCER (ABC) RECEIVING EVEROLIMUS-EXEMESTANE COMBINATION THERAPY (EVE-EXE)
    Toram, N.
    Mahjoubi, R.
    Tang, D.
    [J]. VALUE IN HEALTH, 2017, 20 (05) : A93 - A93
  • [8] Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
    Denise A. Yardley
    Shinzaburo Noguchi
    Kathleen I. Pritchard
    Howard A. Burris
    José Baselga
    Michael Gnant
    Gabriel N. Hortobagyi
    Mario Campone
    Barbara Pistilli
    Martine Piccart
    Bohuslav Melichar
    Katarina Petrakova
    Francis P. Arena
    Frans Erdkamp
    Wael A. Harb
    Wentao Feng
    Ayelet Cahana
    Tetiana Taran
    David Lebwohl
    Hope S. Rugo
    [J]. Advances in Therapy, 2014, 31 : 1008 - 1009
  • [9] Everolimus Added to Exemestane Reduced Bone Markers in Postmenopausal Women with Advanced Breast Cancer (ABC): the BOLERO-2 Trial
    Gnant, M.
    Hortobagyi, G. N.
    Rugo, H.
    Burris, H. A.
    Noguchi, S.
    Pritchard, K. I.
    Baselga, J.
    Sahmoud, T.
    Bauly, H.
    Piccart, M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 : S43 - S43
  • [10] TRINITI-1: Ribociclib plus everolimus (EVE) plus exemestane (EXE) triplet combination in men or postmenopausal women with HR+, HER2-advanced breast cancer (ABC) following progression on a cyclin-dependent kinase (CDK) 4/6 inhibitor
    Bardia, A.
    Hurvitz, S.
    Yardley, D. A.
    Zelnak, A.
    DeMichele, A.
    Clark, A. S.
    Warsi, G.
    Small, T.
    Tucci, C.
    Moulder, S.
    [J]. CANCER RESEARCH, 2017, 77
12345